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An Update on Cancer in American Indians and Alaska
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BACKGROUND. American Indian and Alaska Native (AI/AN) men experience lower
incidence of prostate cancer than other race/ethnic populations in the US, but
racial misclassification of AI/AN men threatens the validity of these estimates. To
the authors’ knowledge, little is known concerning prostate-specific antigen (PSA)
testing in AI/AN men.
METHODS. The authors linked cancer registry data with Indian Health Service
enrollment records to improve race classification. Analyses comparing cancer
incidence rates and stage at diagnosis for AI/AN and non-Hispanic white (NHW)
men for 6 geographic regions focused on counties known to have less race mis-
classification. The authors also used Behavioral Risk Factors Surveillance System
data to characterize PSA testing in AI/AN men.
RESULTS. Prostate cancer incidence rates were generally lower in AI/AN than in
NHW men for all regions combined (rate ratio of 0.68). However, regional variation
was noted among AI/AN men, with incidence rates (per 100,000 population) ranging
from 65.7 in the Southwest to 174.5 on the Northern Plains. The rate of distant stage
disease was somewhat higher among AI/AN (7.8) than NHW (6.2) men. Nationally,
AI/AN men were less likely than NHW men to have undergone recent PSA testing
(48.4% vs 58.0%), with prominent regional variation in screening rates noted.
CONCLUSIONS. Prostate cancer incidence rates and the proportion of men with
recent PSA testing were lower for AI/AN men than for NHW men. However, inci-
dent rates and rate of distant stage varied by region more for AI/AN than for
NHW. Further research is needed among AI/AN men to evaluate strategies for
better understanding the causes of the regional variation in prostate cancer
incidence. Cancer 2008;113(5 suppl):1203–12. Published 2008 by the American
Cancer Society.*
KEYWORDS: prostate cancer, cancer, incidence, American Indian, Alaska Native,
misclassification, National Program of Cancer Registries (NPCR), Surveillance, Epi-
demiology, End Results (SEER), US, health disparity.
P rostate cancer is an important health issue for men in the US,1including American Indian/Alaska Native (AI/AN) men.2 It is the
second-leading cause of cancer death for men of all races combined
and for AI/AN men.3 Largely because of race misclassification, the
accuracy of prostate cancer incidence and stage data among AI/AN
men has been uncertain; prior publications on the subject focused
on specific geographic regions4,5 and thus were not generalizable to
other AI/AN populations. Furthermore, the association between can-
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cer incidence and prostate-specific antigen (PSA)
testing among AI/AN men has not been well
described.
The purpose of the current study was to better
estimate prostate cancer incidence and stage at diag-
nosis in AI/AN men, using techniques to minimize
race misclassification. We present these data by geo-
graphic region and for all regions combined. We also
described patterns of PSA testing among AI/AN men,
identified the demographic and behavioral factors
associated with testing, and evaluated ecologic asso-
ciations of PSA testing with prostate cancer incidence.
MATERIALS AND METHODS
Detailed descriptions of the data sources and meth-
ods used for this analysis are found elsewhere in this
supplement.6
Cancer Cases
We identified cancer cases using data collected by
the National Program of Cancer Registries of the
Centers for Disease Control and Prevention (CDC)
and the Surveillance, Epidemiology, and End Results
(SEER) Program of the National Cancer Institute
(NCI).7 Registries coded primary cancer site and his-
tology data according to the third edition of the
International Classification of Diseases for Oncology
(ICD-O).8 We used data regarding invasive cancers
(ICD-O-3 C619) to calculate incidence rates. Included
cases are from state registries that agreed to partici-
pate in this project and met the US Cancer Statistics
standards for high-quality data.7
We classified race by combining information
from 2 sources: 1) data linkages with Indian Health
Service (IHS) patient registration records and 2) the
multiple race fields in cancer registry records. The
IHS provides medical services to AI/AN persons who
are members, or descendents of members, of feder-
ally recognized tribes. To reduce race misclassifica-
tion, states linked all case records with the IHS
patient registration database to identify AI/AN cases
misclassified as some other racial group. Further
details about coding rules for multiple races are
described elsewhere in this supplement.6
To further improve race classification, we focused
analyses on Contract Health Service Delivery Area
(CHSDA) counties (Fig. 1), which generally contain
federally recognized tribal lands or are adjacent to
tribal lands. The proportions of AI/AN in relation to
total population are higher in CHSDA counties than in
non-CHSDA counties, and data indicate less race mis-
classification for AI/AN in these counties.9 Approxi-
mately 56% of the US AI/AN population resides in
CHSDA counties. This proportion varies by IHS region:
Alaska: 100%; East: 13.1%; Northern Plains: 59.0%;
Southern Plains: 64.1%; Pacific Coast: 55.6%; and
Southwest: 87.5% (in each region, the proportion of
AI/AN in CHSDA counties to AI/AN in all counties.) In
addition, our analyses stratified incidence rates by IHS
regions (Alaska, Pacific Coast, Northern Plains, South-
ern Plains, Southwest, and East) to evaluate the geo-
graphic variation of cancer incidence in the AI/AN
population (Fig. 1). Additional details concerning
CHSDA and IHS are provided elsewhere.6
Stage of disease data spanned changes in SEER
summary stage coding. Stage was coded according to
SEER Summary Stage 1977 rules for diagnosis years
1999 to 2000 and according to SEER summary stage
2000 rules for diagnosis years 2001 to 2003; colla-
borative stage data, first reported for 2004, were not
available for analysis. We reported stage data for
2001 to 2003 because of significant changes in cod-
ing local and regional stage disease between the 2
staging systems.10,11
Population Estimates
The NCI makes further refinements to population esti-
mates produced by the CDC and the Census Bureau
regarding race and county geographic codes; the esti-
mates for the period 1999 to 2004 were used as
denominators for the rate calculations in this report.12
PSA Testing and Demographic, Health, and
Socioeconomic Indicators
We used data from the Behavioral Risk Factor Sur-
veillance System (BRFSS) to characterize PSA testing
in the AI/AN and NHW populations and to evaluate
FIGURE 1. State and Contract Health Service Delivery Area (CHSDA) coun-
ties used in cancer incidence analyses for the American Indian and Alaska
Native population are shown by Region.
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the influence of demographic, health, and socioeco-
nomic factors on PSA testing. BRFSS is a cross-sec-
tional telephone survey conducted by all state health
departments and the District of Columbia. PSA test-
ing questions were part of the BRFSS core module in
2001, 2002, 2004, and 2006. Respondents were asked
if they had ever had a PSA test and the time since
their last test. BRFSS data presented here include
data from all counties of the 50 states and the
District of Columbia (ie, are not limited to CHSDA
counties). More detailed methodology regarding the
BRFSS has been published in this supplement and
elsewhere.13,14
Statistical Analyses
Two sets of basic descriptive statistics are provided
for AI/AN and NHW men: 1) data from CHSDA
counties in all states that meet quality criteria and 2)
data from all counties in all states that meet cancer
registry data quality criteria (referred to as ‘All Coun-
ties’). In addition, CHSDA and All Counties data are
provided for each IHS region. The results described
in the text refer to persons who resided in CHSDA
counties, unless otherwise noted. Additional informa-
tion regarding cases and population coverage is
available elsewhere in this supplement.6
For AI/AN and NHW populations, prostate cancer
incidence rates are expressed per 100,000 and age-
adjusted to the 2000 US standard population using 19
age groups (Census P25-1130). In addition, we per-
formed a stratified analysis by 4 age groups (<50, 50-64,
65-74, and 75 1 years) based on screening recommen-
dations,15 and the provision of Medicare benefits for
those aged 65 years. Age-group specific rates are also
age-adjusted within each age category. Stage-specific
rates and percent distributions of stage of disease at di-
agnosis are also age-adjusted. Age-adjusted rates were
generated using SEER*Stat Software (version 6.3.6).16
For all analyses, exact counts were suppressed when the
category of interest contained 5 or fewer cases.
Using the age-adjusted incidence rates, standar-
dized rate ratios (RRs) were calculated for AI/AN
men using NHW rates for comparison. Confidence
intervals (CIs) for age-adjusted rates and standar-
dized RRs were calculated based on methods
described by Tiwari et al17 using SEER*Stat 6.3.6.16
We report the proportions and 95% CIs for PSA
testing within the last year for all male AI/AN and
NHW BRFSS respondents aged 50 to 75 years, overall
and stratified by region. We also report the propor-
tions and 95% CIs of those with recent PSA testing
by key demographic, socioeconomic, and health
behavior factors. The BRFSS data presented herein
are not restricted to CHSDA counties.
RESULTS
In CHSDA and All Counties, the prostate cancer inci-
dence rate for all regions combined for AI/AN men
was lower than the rate for NHW men (Table 1). The
TABLE 1
Prostate Cancer Incidence by Indian Health Service Region for American Indians/Alaska Nativesa and Non-Hispanic Whites, US, 1999-2004
CHSDA Counties All Counties
IHS Region
AI/AN
Count
AI/AN
Rateb
95% CI for
AI/AN Rate
NHW
Rateb
Rate Ratio
(AI/AN:NHW)
95% CI for
Rate Ratio
AI/AN
Count
AI/AN
Rateb
95% CI for
AI/AN Rate
NHW
Rateb
Rate Ratio
(AI/AN:NHW)
95% CI for
Rate Ratio
Northern Plains 499 174.5 157.8-192.4 162.2 1.08 0.97-1.19 651 133.6 122.2-145.7 161.7 0.83c 0.76-0.90
Alaskad 124 78.3 63.7-95.0 180.7 0.43c 0.35-0.53 124 78.3 63.7-95.0 180.7 0.43c 0.35-0.53
Southern Plains 834 156.7 145.7-168.3 146.5 1.07 0.99-1.15 930 126.6 118.1-135.6 147.8 0.86c 0.80-0.92
Pacific Coast 447 83.2 74.9-92.0 160.8 0.52c 0.47-0.57 586 60.6 55.4-66.2 161.6 0.38c 0.34-0.41
East 114 83.9 68.1-102.0 155.9 0.54c 0.44-0.65 646 63.8 58.6-69.3 149.7 0.43c 0.39-0.46
Southwest 457 65.7 59.5-72.2 133.8 0.49c 0.44-0.54 492 63.6 57.8-69.7 146.9 0.43c 0.39-0.47
Total 2475 105.6 101.2-110.1 154.4 0.68c 0.66-0.71 3429 83.5 80.5-86.6 153.4 0.54c 0.52-0.56
IHS indicates Indian Health Service; CHSDA, Contract Health Service Delivery Areas; AI/AN, American Indian/Alaska Native; 95% CI, 95% confidence interval; NHW, non-Hispanic white.
a AI/AN race is reported by National Program of Cancer Registries and Surveillance, Epidemiology, and End Results registries or through linkage with the IHS patient registration database. AI/AN persons of His-
panic origin are included.
b Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population (19 age groups, Census P25-1130).
c Rate ratio is statistically significant (P<.05).
d Rates and rate ratios for Alaska in the CHSDA Counties section is the same as those in the All Counties section because all counties in Alaska are CHSDA counties.
Years of data and registries used: 1999 to 2004 (41 states and DC; *indicates states with at least 1 county designated as CHSDA): Alaska,* Alabama,* Arkansas, Arizona,* California,* Colorado,* Connecticut,* Dis-
trict of Columbia, Delaware, Florida,* Georgia, Hawaii, Iowa,* Idaho,* Illinois, Indiana,* Kentucky, Louisiana,* Massachusetts,* Maine,* Michigan,* Minnesota,* Missouri, Montana,* North Carolina,* Nebraska,*
New Hampshire, New Jersey, New Mexico,* Nevada,* New York,* Ohio, Oklahoma,* Oregon,* Pennsylvania,* Rhode Island,* Texas,* Utah,* Washington,* Wisconsin,* West Virginia, and Wyoming*; 1999 and 2002
to 2004: North Dakota*; 2001 to 2004: South Dakota*; 2003 to 2004: Mississippi* and Virginia; 2004: Tennessee.
Percent regional coverage of AI/AN in CHSDA counties to AI/AN in all counties: Alaska: 100%; East: 13.1%; Northern Plains: 59.0%; Southern Plains: 64.1%; Pacific Coast: 55.6%; Southwest: 87.5%.
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rate of prostate cancer in AI/AN men residing in
CHSDA counties was higher than the AI/AN rate for
All Counties for 5 of 6 regions and for all regions
combined. Little variation was noted between
CHSDA and All Counties for NHW men. AI/AN inci-
dence rates in CHSDA counties varied widely by
region and ranged from 65.7 (per 100,000 males) in
the Southwest to 174.5 in the Northern Plains,
whereas NHW rates ranged from 133.8 in the South-
west to 180.7 in Alaska. AI/AN rates were highest in
the Plains regions, where they were similar to NHW
men, but nearly 2-fold or more higher than the rates
for AI/AN men in the remaining regions.
When examined by age group, among those
residing in CHSDA counties, AI/AN men in the 50
years to 64 years and 65 years to 74 years age groups
had lower incidence rates compared with NHW men,
except in the Northern and Southern Plains, in which
the rates were similar (Table 2). For the age group
75 years, AI/AN men in the Northern Plains and
Southern Plains had higher incidence rates than
NHW men (RR of 1.44 [95% CI, 1.19-1.74] and RR of
1.19 [95% CI, 1.03-1.37], respectively).
For AI/AN males, 67.5% of prostate cancers were
diagnosed at the localized stage versus 76.4% for
NHW men (Table 3). Conversely, for AI/AN men,
7.4% of prostate cancers were diagnosed at the dis-
tant stage compared with 4.0% for NHW men; the
differences in incidence rates of late state disease
were not as marked (7.8 vs 6.2) and were mostly
because of a high rate among AI/AN in the Northern
Plains. The distributions of cancers diagnosed at the
regional stage were similar between AI/AN and NHW
men. Finally, the percentage of unstaged cancers was
greater in AI/AN men (16.0%) than in NHW men
(10.0%).
Table 4 presents the prevalence in the 50 states
and the District of Columbia and by region of PSA
testing by demographics and measures of socioeco-
nomic status and access to care. For all regions com-
bined, the prevalence of recent PSA testing was higher
for NHW than for AI/AN men (58.0% and 48.4%,
respectively). AI/AN men in the Southern Plains had
the highest prevalence (54.9%), whereas those in
Alaska had the lowest (28.7%). Overall, increasing age
was associated with a higher prevalence of recent PSA
testing for NHW and AI/AN men. However, among
AI/AN men, there was no consistent relation noted
between age and testing within regions. Having
healthcare coverage; having higher levels of both edu-
cational attainment and income; being current with
colorectal cancer screening; being married; reporting
excellent, very good, or good health status; being a
nonsmoker; and being employed or retired were all
TABLE 2
Prostate Cancer Invasive Incidence Ratesa and Rate Ratiosb by Age and Indian Health Service Region for American Indians/Alaska Nativesc and
Non-Hispanic Whites, CHSDA Counties, US, 1999 to 2004
<50 Years 50-64 Years 65-74 Years 751 Years
IHS Region
AI/AN
Ratea
NHW
Ratea RRb 95% CI
AI/AN
Ratea
NHW
Ratea RRb 95% CI
AI/AN
Ratea
NHW
Ratea RRb 95% CI
AI/AN
Ratea
NHW
Ratea RRb 95% CI
CHSDA counties
Northern Plains 5.1 4.3 1.19 0.73-1.81 257.6 303.4 0.85b 0.73-0.98 893.7 953.3 0.94 0.80-1.09 1212.6 839.5 1.44b 1.19-1.74
Alaska 2.0 4.6 0.43 0.11-1.11 162.1 313.7 0.52b 0.39-0.68 297.5 1043.1 0.29b 0.20-0.40 545.3 1017.3 0.54b 0.35-0.80
Southern Plains 2.3 3.6 0.63 0.33-1.08 237.6 249.6 0.95 0.84-1.08 879.5 830.7 1.06 0.94-1.18 1016.7 854.6 1.19b 1.03-1.37
Pacific Coast 1.6 4.2 0.39c 0.20-0.67 133.8 305.2 0.44c 0.37-0.51 521.4 929.9 0.56c 0.48-0.65 455.8 838.7 0.54c 0.43-0.68
East 2.9 4.6 0.64 0.21-1.46 172.5 301.5 0.57c 0.43-0.75 399.5 901.9 0.44c 0.30-0.62 489.4 792.6 0.62c 0.39-0.92
Southwest 0.9 4.0 0.24c 0.10-0.46 92.8 273.4 0.34c 0.28-0.40 358.8 769.0 0.47c 0.40-0.54 453.8 648.8 0.70c 0.58-0.83
Total CHSDA 2.1 4.2 0.51c 0.39-0.65 165.2 295.1 0.56c 0.52-0.60 578.1 892.5 0.65c 0.61-0.69 681.1 798.6 0.85c 0.79-0.92
Source: Cancer registries in the National Program of Cancer Registries of the Centers for Disease Control and Prevention and/or the Surveillance, Epidemiology, and End Results program of the National Cancer
Institute.
IHS indicates Indian Health Service; CHDSA, Contract Health Service Delivery Areas; AI/AN, American Indian/Alaska Native; NHW, non-Hispanic white; RR, rate ratio.
a Rates are per 100,000 persons and are age-adjusted to the 2000 US standard population (19 age groups, Census P25-1130).
b Rate ratios are calculated in SEERaStat prior to rounding of rates and may not equal rate ratios calculated from rates presented in the table.
c Rate ratio is statistically significant (P<.05).
Years of data and registries used: 1999 to 2004 (41 states and DC; *indicates states with at least 1 county designated as CHSDA): Alaska,* Alabama,* Arkansas, Arizona,* California,* Colorado,* Connecticut,* Dis-
trict of Columbia, Delaware, Florida,* Georgia, Hawaii, Iowa,* Idaho,* Illinois, Indiana,* Kentucky, Louisiana,* Massachusetts,* Maine,* Michigan,* Minnesota,* Missouri, Montana,* North Carolina,* Nebraska,*
New Hampshire, New Jersey, New Mexico,* Nevada,* New York,* Ohio, Oklahoma,* Oregon,* Pennsylvania,* Rhode Island,* Texas,* Utah,* Washington,* Wisconsin,* West Virginia, and Wyoming*; 1999 and 2002
to 2004: North Dakota*; 2001 to 2004: South Dakota*; 2003 to 2004: Mississippi* and Virginia; 2004: Tennessee.
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associated with increased PSA testing for NHW and
AI/AN men, both nationally and regionally.
DISCUSSION
There are several findings to emphasize from the
current study. First, the prostate cancer incidence
rate for AI/AN men for all regions combined is lower
than for NHW men living in the same counties; how-
ever, the rate is higher than reported previously,18-22
although differences in age standardization of rates
may make the comparison difficult. Second, as with
other cancer types,23 AI/AN men demonstrate
marked regional variation in prostate cancer inci-
dence rates in comparison with NHW men. Third,
our data indicate that AI/AN men experience slightly
higher rates and percentages of distant stage disease
than NHW men. Finally, our data also demonstrate
lower rates of PSA testing in AI/AN men than in
NHW men in all regions.
There are several possible explanations for the
lower prostate cancer incidence rates noted among
AI/AN men. First, PSA screening primarily detects
early–stage cancers.24 Many screen-detected early
stage prostate cancers are indolent, non–life-threat-
ening lesions that would not have become clinically
apparent in the absence of screening.25 Therefore, a
lower prevalence of prostate cancer screening will
result in lower incidence rates.26 The BRFSS data
presented herein demonstrated that PSA screening
rates are lower for AI/AN men in every region when
compared with NHW men, often markedly so. Much
of the difference observed in prostate cancer inci-
dence rates between AI/AN and NHW men may be
explained by differences in PSA screening in the
population.
Second, an increasing body of evidence points to
an inverse correlation between type 2 diabetes
mellitus and prostate cancer.27-33 AI/AN men (and
women) have the highest prevalence of type 2 diabe-
tes mellitus of any race/ethnic group in the US.34–38
Diabetes-related hypoinsulinemia and low androgen-
icity are hypothesized to reduce the risk for prostate
cancer.39 Other hypotheses for this apparent protec-
tive effect include decreased testosterone levels, a
common finding in males with type 2 diabetes32,40,41;
the potential beneficial effects of drugs used to treat
diabetes or other conditions42,43; and the possible
role of renal failure.44 The role that diabetes may
play in prostate cancer in AI/AN men is unclear and
is likely to have much less influence on overall rates
than PSA screening.
The current study data also demonstrate a striking
regional variation in AI/AN prostate cancer incidenceTA
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rates, exceeding that noted among NHW men. The
rates for AI/AN men living on either the Northern or
Southern Plains approach and even surpass those for
NHW men, and are approximately double the rates
reported for AI/AN men in all other regions. By con-
trast, the NHW rates reveal at most 35% regional
variation. This marked degree of regional variation in
prostate cancer rates noted among AI/AN men mirrors
that reported for rates of other leading cancer types
among both men and women.3,23,45–47 Although this
variation in prostate cancer incidence modestly tracks
differences in self-reported BRFSS prevalence of PSA
testing among AI/AN men, differences in testing alone
are not likely to explain all the variation. For 1 reason,
our BRFSS data demonstrate an inconsistent correla-
tion between PSA testing prevalence and prostate can-
cer incidence, including localized stage disease, among
the AI/AN men in our 6 different regions. Beyond the
possible effects of screening differences and the few
obviously tobacco-related cancers—notably lung and
urinary bladder—we really cannot explain this varia-
tion noted for multiple cancer types. These data
emphasize the need for etiologic studies designed to
elucidate regional variation in prostate cancer inci-
dence and other cancers that can assist in prioritizing
future cancer control efforts.
Although routine screening with PSA is not
recommended by the US Preventive Services Task
Force nor by most other major health organizations,
it is still widely used by clinicians. Therefore, the dif-
ferences in PSA testing between AI/AN and NHW
men may reflect similar disparities in health access
as noted for other cancers, such as breast and color-
ectal, for which screening recommendations are
widely accepted.44,49 Cultural issues may play a role
in the limited use of PSA screening tests in AI/AN
populations. Several studies, involving only AI/AN
females, have examined relations between cultural
beliefs and practices, or ‘‘traditionality,’’ and receipt
of breast and/or cervical cancer screening.50–55
Although the results of these and other studies were
generally mixed, future research regarding the influ-
ences of traditionality on receipt of cancer screening
tests (eg, for colorectal cancer) or seeking care when
symptoms develop should include AI/AN men.
The current study has several important strengths.
We used the most current, complete, and accurate
data available regarding prostate cancer incidence and
stage at diagnosis for AI/AN males. Specifically, few
previous studies have reached the broad coverage
achieved in this analysis. In addition, our ability to
conduct data linkages and to restrict our analyses to
CHSDA counties has likely improved the classification
of AI/AN race in participating cancer registries. Finally,
our study includes BRFSS prostate cancer test receipt
data on AI/AN men analyzed by 6 geographic regions.
The current study has several important limita-
tions. First, the analyses presented here for AI/AN
populations are based on residents of CHSDA coun-
ties and excluded many AI/AN residents in urban
areas not part of CHSDA counties; therefore, the
findings do not represent all AI/AN populations in
the US or in individual IHS regions, particularly the
East.6 There may be significant differences in cancer
risk–related and screening behaviors between the AI/
AN and NHW men who live in these selected coun-
ties and those not living in those counties. Second,
although linkage with IHS patient registration data-
bases improves the race classification for AI/AN
cases, AI/AN persons who are not eligible for IHS
services are not represented in the IHS database.
Third, BRFSS data are limited by being self-reported,
by selection bias related to the sampling strategy and
the relatively low response rate,56 by the small num-
bers of AI/AN participants, and perhaps most impor-
tantly in this case, by the fact that these data were
not limited to CHSDA counties. Finally, we did not
provide comparable prostate cancer mortality data
among AI/AN and NHW men in the CHSDA coun-
ties. Other reports have noted that prostate cancer
mortality in AI/AN men in the Plains regions for
time periods similar to our incidence analyses
exceeds that of NHW men.45,57 Future analyses could
determine whether there is an association between
lack of PSA testing, presenting at advanced stage,
and mortality. In addition, linking mortality data
with cancer registry data linked to the IHS patient
registration database could reveal stage-specific mor-
tality rates for AI/AN and NHW men, and be able to
evaluate whether survival differences were related to
access to/receipt of treatment.
In conclusion, AI/AN men have a generally lower
prostate cancer incidence than NHW men and lower
rates of PSA testing. The current study data also
demonstrate marked regional variation in cancer
incidence rates among AI/AN persons. Future
research should include data regarding prostate can-
cer mortality for AI/AN men to better correlate fac-
tors with disease stage, treatment decisions, and
outcomes. In addition, future research among AI/AN
men should also examine the role of diabetes status
and duration as well as other patient factors on pros-
tate cancer screening, incidence, and outcomes.
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